TY - JOUR
T1 - ELOVL4 Mutations That Cause Spinocerebellar Ataxia-34 Differentially Alter Very Long Chain Fatty Acid Biosynthesis
AU - Gyening, Yeboah Kofi
AU - Chauhan, Neeraj Kumar
AU - Tytanic, Madison
AU - Ea, Vicki
AU - Brush, Richard S.
AU - Agbaga, Martin Paul
N1 - Funding Information:
The authors are very grateful to Robert E. Anderson, MD, PhD for his helpful insights and discussions. We also thank Janet Asiedua Faakye and Kathy Kyler M.S., M.A.A.L of OUHSC for reading and helping in editing the manuscript. Support for this work was provided by NIH grants R01 EY030513; R21 AR076035 and Oklahoma Center for Advancement of Science and Technology (OCAST) (MPA), Bright Focus Eye Foundation (MPA), and Knight Templars Eye Foundation (MPA). Other sources of support include Multi-PI Team Science grant from Presbyterian Health Foundation, NIH grants P30EY021725 (MC), and unrestricted grant support from Research to Prevent Blindness to the Dean McGee Eye Institute.
Publisher Copyright:
© 2022 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.
PY - 2023/1
Y1 - 2023/1
N2 - The FA Elongase-4 (ELOVL4) enzyme mediates biosynthesis of both very long chain (VLC)PUFAs and VLC-saturated FA (VLC-SFAs). VLC-PUFAs play critical roles in retina and sperm function, whereas VLC-SFAs are predominantly associated with brain function and maintenance of the skin permeability barrier. While some ELOVL4 mutations cause Autosomal Dominant Stargardt-like Macular Dystrophy (STGD3), other ELOVL4 point mutations, such as L168F and W246G, affect the brain and/or skin, leading to Spinocerebellar Ataxia-34 (SCA34) and Erythrokeratodermia variabilis. The mechanisms by which these ELOVL4 mutations alter VLC-PUFA and VLC-SFA biosynthesis to cause the different tissue-specific pathologies are not well understood. To understand how these mutations alter VLC-PUFA and VLC-SFA biosynthesis, we expressed WT-ELOVL4, L168F, and W246G ELOVL4 variants in cell culture and supplemented the cultures with VLC-PUFA or VLC-SFA precursors. Total lipids were extracted, converted to FA methyl esters, and quantified by gas chromatography. We showed that L168F and W246G mutants were capable of VLC-PUFA biosynthesis. W246G synthesized and accumulated 32:6n3, while L168F exhibited gain of function in VLC-PUFA biosynthesis as it made 38:5n3, which we did not detect in WT-ELOVL4 or W246G-expressing cells. However, compared with WT-ELOVL4, both L168F and W246G mutants were deficient in VLC-SFA biosynthesis, especially the W246G protein, which showed negligible VLC-SFA biosynthesis. These results suggest VLC-PUFA biosynthetic capabilities of L168F and W246G in the retina, which may explain the lack of retinal phenotype in SCA34. Defects in VLC-SFA biosynthesis by these variants may be a contributing factor to the pathogenic mechanism of SCA34 and Erythrokeratodermia variabilis.
AB - The FA Elongase-4 (ELOVL4) enzyme mediates biosynthesis of both very long chain (VLC)PUFAs and VLC-saturated FA (VLC-SFAs). VLC-PUFAs play critical roles in retina and sperm function, whereas VLC-SFAs are predominantly associated with brain function and maintenance of the skin permeability barrier. While some ELOVL4 mutations cause Autosomal Dominant Stargardt-like Macular Dystrophy (STGD3), other ELOVL4 point mutations, such as L168F and W246G, affect the brain and/or skin, leading to Spinocerebellar Ataxia-34 (SCA34) and Erythrokeratodermia variabilis. The mechanisms by which these ELOVL4 mutations alter VLC-PUFA and VLC-SFA biosynthesis to cause the different tissue-specific pathologies are not well understood. To understand how these mutations alter VLC-PUFA and VLC-SFA biosynthesis, we expressed WT-ELOVL4, L168F, and W246G ELOVL4 variants in cell culture and supplemented the cultures with VLC-PUFA or VLC-SFA precursors. Total lipids were extracted, converted to FA methyl esters, and quantified by gas chromatography. We showed that L168F and W246G mutants were capable of VLC-PUFA biosynthesis. W246G synthesized and accumulated 32:6n3, while L168F exhibited gain of function in VLC-PUFA biosynthesis as it made 38:5n3, which we did not detect in WT-ELOVL4 or W246G-expressing cells. However, compared with WT-ELOVL4, both L168F and W246G mutants were deficient in VLC-SFA biosynthesis, especially the W246G protein, which showed negligible VLC-SFA biosynthesis. These results suggest VLC-PUFA biosynthetic capabilities of L168F and W246G in the retina, which may explain the lack of retinal phenotype in SCA34. Defects in VLC-SFA biosynthesis by these variants may be a contributing factor to the pathogenic mechanism of SCA34 and Erythrokeratodermia variabilis.
KW - autosomal dominant Stargardt macular dystrophy
KW - elongation of very long chain fatty acid-4
KW - erythrokeratodermia variabilis
KW - eye/retina
KW - fatty acid metabolism
KW - lipids
KW - omega-3 fatty acids
KW - saturated fatty acid
KW - tissue-specific pathologies
KW - very long chain polyunsaturated fatty acids
UR - http://www.scopus.com/inward/record.url?scp=85147047303&partnerID=8YFLogxK
U2 - 10.1016/j.jlr.2022.100317
DO - 10.1016/j.jlr.2022.100317
M3 - Article
C2 - 36464075
AN - SCOPUS:85147047303
SN - 0022-2275
VL - 64
JO - Journal of Lipid Research
JF - Journal of Lipid Research
IS - 1
M1 - 100317
ER -